These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

333 related items for PubMed ID: 30021904

  • 1. Enhancer Control of MicroRNA miR-155 Expression in Epstein-Barr Virus-Infected B Cells.
    Wood CD, Carvell T, Gunnell A, Ojeniyi OO, Osborne C, West MJ.
    J Virol; 2018 Oct 01; 92(19):. PubMed ID: 30021904
    [Abstract] [Full Text] [Related]

  • 2. EBNA2 driven enhancer switching at the CIITA-DEXI locus suppresses HLA class II gene expression during EBV infection of B-lymphocytes.
    Su C, Lu F, Soldan SS, Lamontagne RJ, Tang HY, Napoletani G, Farrell PJ, Tempera I, Kossenkov AV, Lieberman PM.
    PLoS Pathog; 2021 Aug 01; 17(8):e1009834. PubMed ID: 34352044
    [Abstract] [Full Text] [Related]

  • 3. Epstein-Barr Virus Nuclear Antigen 3 (EBNA3) Proteins Regulate EBNA2 Binding to Distinct RBPJ Genomic Sites.
    Wang A, Welch R, Zhao B, Ta T, Keleş S, Johannsen E.
    J Virol; 2015 Dec 30; 90(6):2906-19. PubMed ID: 26719268
    [Abstract] [Full Text] [Related]

  • 4. Epstein-Barr Virus Nuclear Antigen Leader Protein Coactivates EP300.
    Wang C, Zhou H, Xue Y, Liang J, Narita Y, Gerdt C, Zheng AY, Jiang R, Trudeau S, Peng CW, Gewurz BE, Zhao B.
    J Virol; 2018 May 01; 92(9):. PubMed ID: 29467311
    [Abstract] [Full Text] [Related]

  • 5. Epstein-Barr virus exploits intrinsic B-lymphocyte transcription programs to achieve immortal cell growth.
    Zhao B, Zou J, Wang H, Johannsen E, Peng CW, Quackenbush J, Mar JC, Morton CC, Freedman ML, Blacklow SC, Aster JC, Bernstein BE, Kieff E.
    Proc Natl Acad Sci U S A; 2011 Sep 06; 108(36):14902-7. PubMed ID: 21746931
    [Abstract] [Full Text] [Related]

  • 6. Counteracting effects of cellular Notch and Epstein-Barr virus EBNA2: implications for stromal effects on virus-host interactions.
    Rowe M, Raithatha S, Shannon-Lowe C.
    J Virol; 2014 Oct 06; 88(20):12065-76. PubMed ID: 25122803
    [Abstract] [Full Text] [Related]

  • 7. EBNA2-deleted Epstein-Barr virus (EBV) isolate, P3HR1, causes Hodgkin-like lymphomas and diffuse large B cell lymphomas with type II and Wp-restricted latency types in humanized mice.
    Li C, Romero-Masters JC, Huebner S, Ohashi M, Hayes M, Bristol JA, Nelson SE, Eichelberg MR, Van Sciver N, Ranheim EA, Scott RS, Johannsen EC, Kenney SC.
    PLoS Pathog; 2020 Jun 06; 16(6):e1008590. PubMed ID: 32542010
    [Abstract] [Full Text] [Related]

  • 8. Epstein-Barr virus nuclear antigen 3A partially coincides with EBNA3C genome-wide and is tethered to DNA through BATF complexes.
    Schmidt SC, Jiang S, Zhou H, Willox B, Holthaus AM, Kharchenko PV, Johannsen EC, Kieff E, Zhao B.
    Proc Natl Acad Sci U S A; 2015 Jan 13; 112(2):554-9. PubMed ID: 25540416
    [Abstract] [Full Text] [Related]

  • 9. Latent Epstein-Barr virus infection collaborates with Myc over-expression in normal human B cells to induce Burkitt-like Lymphomas in mice.
    Bristol JA, Nelson SE, Ohashi M, Casco A, Hayes M, Ranheim EA, Pawelski AS, Singh DR, Hodson DJ, Johannsen EC, Kenney SC.
    PLoS Pathog; 2024 Apr 13; 20(4):e1012132. PubMed ID: 38620028
    [Abstract] [Full Text] [Related]

  • 10. Epstein-Barr virus-encoded EBNA2 alters immune checkpoint PD-L1 expression by downregulating miR-34a in B-cell lymphomas.
    Anastasiadou E, Stroopinsky D, Alimperti S, Jiao AL, Pyzer AR, Cippitelli C, Pepe G, Severa M, Rosenblatt J, Etna MP, Rieger S, Kempkes B, Coccia EM, Sui SJH, Chen CS, Uccini S, Avigan D, Faggioni A, Trivedi P, Slack FJ.
    Leukemia; 2019 Jan 13; 33(1):132-147. PubMed ID: 29946193
    [Abstract] [Full Text] [Related]

  • 11. Epstein-Barr virus-encoded EBNA2 downregulates ICOSL by inducing miR-24 in B-cell lymphoma.
    Leopizzi M, Mundo L, Messina E, Campolo F, Lazzi S, Angeloni A, Marchese C, Leoncini L, Giordano C, Slack F, Trivedi P, Anastasiadou E.
    Blood; 2024 Feb 01; 143(5):429-443. PubMed ID: 37847858
    [Abstract] [Full Text] [Related]

  • 12. EBV nuclear antigen EBNALP dismisses transcription repressors NCoR and RBPJ from enhancers and EBNA2 increases NCoR-deficient RBPJ DNA binding.
    Portal D, Zhao B, Calderwood MA, Sommermann T, Johannsen E, Kieff E.
    Proc Natl Acad Sci U S A; 2011 May 10; 108(19):7808-13. PubMed ID: 21518914
    [Abstract] [Full Text] [Related]

  • 13. The nuclear chaperone nucleophosmin escorts an Epstein-Barr Virus nuclear antigen to establish transcriptional cascades for latent infection in human B cells.
    Liu CD, Chen YL, Min YL, Zhao B, Cheng CP, Kang MS, Chiu SJ, Kieff E, Peng CW.
    PLoS Pathog; 2012 May 10; 8(12):e1003084. PubMed ID: 23271972
    [Abstract] [Full Text] [Related]

  • 14. EBNA2-EBF1 complexes promote MYC expression and metabolic processes driving S-phase progression of Epstein-Barr virus-infected B cells.
    Beer S, Wange LE, Zhang X, Kuklik-Roos C, Enard W, Hammerschmidt W, Scialdone A, Kempkes B.
    Proc Natl Acad Sci U S A; 2022 Jul 26; 119(30):e2200512119. PubMed ID: 35857872
    [Abstract] [Full Text] [Related]

  • 15. Epstein-Barr virus nuclear antigen 2 trans-activates the cellular antiapoptotic bfl-1 gene by a CBF1/RBPJ kappa-dependent pathway.
    Pegman PM, Smith SM, D'Souza BN, Loughran ST, Maier S, Kempkes B, Cahill PA, Simmons MJ, Gélinas C, Walls D.
    J Virol; 2006 Aug 26; 80(16):8133-44. PubMed ID: 16873269
    [Abstract] [Full Text] [Related]

  • 16. Oncogenic IRFs provide a survival advantage for Epstein-Barr virus- or human T-cell leukemia virus type 1-transformed cells through induction of BIC expression.
    Wang L, Toomey NL, Diaz LA, Walker G, Ramos JC, Barber GN, Ning S.
    J Virol; 2011 Aug 26; 85(16):8328-37. PubMed ID: 21680528
    [Abstract] [Full Text] [Related]

  • 17. Identification of Epstein-Barr virus (EBV) nuclear antigen 2 (EBNA2) target proteins by proteome analysis: activation of EBNA2 in conditionally immortalized B cells reflects early events after infection of primary B cells by EBV.
    Schlee M, Krug T, Gires O, Zeidler R, Hammerschmidt W, Mailhammer R, Laux G, Sauer G, Lovric J, Bornkamm GW.
    J Virol; 2004 Apr 26; 78(8):3941-52. PubMed ID: 15047810
    [Abstract] [Full Text] [Related]

  • 18. First Days in the Life of Naive Human B Lymphocytes Infected with Epstein-Barr Virus.
    Pich D, Mrozek-Gorska P, Bouvet M, Sugimoto A, Akidil E, Grundhoff A, Hamperl S, Ling PD, Hammerschmidt W.
    mBio; 2019 Sep 17; 10(5):. PubMed ID: 31530670
    [Abstract] [Full Text] [Related]

  • 19. RUNX super-enhancer control through the Notch pathway by Epstein-Barr virus transcription factors regulates B cell growth.
    Gunnell A, Webb HM, Wood CD, McClellan MJ, Wichaidit B, Kempkes B, Jenner RG, Osborne C, Farrell PJ, West MJ.
    Nucleic Acids Res; 2016 Jun 02; 44(10):4636-50. PubMed ID: 26883634
    [Abstract] [Full Text] [Related]

  • 20. The NP9 protein encoded by the human endogenous retrovirus HERV-K(HML-2) negatively regulates gene activation of the Epstein-Barr virus nuclear antigen 2 (EBNA2).
    Gross H, Barth S, Pfuhl T, Willnecker V, Spurk A, Gurtsevitch V, Sauter M, Hu B, Noessner E, Mueller-Lantzsch N, Kremmer E, Grässer FA.
    Int J Cancer; 2011 Sep 01; 129(5):1105-15. PubMed ID: 21710493
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.